registries classified tumor histology, tumor Objectives. We examined geographic differences and trends in incidence and mortality of ovarian and uterine cancer in American Indian/Alaska Native (AI/AN) women.
Ovarian and uterine cancers are among the top 10 leading causes of cancer deaths and incidence among US women. In 2009, 14 436 deaths resulted from ovarian cancer and 7713 deaths resulted from cancer of the uterine corpus. Additionally, 20 460 new cases of ovarian cancer and 44 192 cases of cancer of the uterine corpus occurred in the United States, accounting for 3% and 6% of all cancer among women, respectively. 1 Incidence rates (IRs) for ovarian cancer decreased from 2005 to 2009, and although ovarian cancer still causes more deaths than any other cancer of the female reproductive system, the average death rate for ovarian cancer also decreased by 2.0% per year during this time period. 1 Alternatively, both death rates and IRs increased for uterine cancer among all women from 2005 to 2009. 2 Cancer, including ovarian and uterine cancer, is a major public health concern in American Indian/Alaska Native (AI/AN) communities. 3 Studies examining cancer incidence patterns among AI/AN populations have generally been limited to restricted time intervals or selected geographic regions. 4---12 Additionally, misclassification of AI/AN race in central cancer registry data and on death certificates has led to underestimation of cancer burden in these populations. 13, 14 Previous studies have documented misclassification of AI/AN persons as another race in central cancer registry data and that the extent of variation varies by registry. 15---17 Arias et al. 14 reported that approximately 42% of AI/AN decedents were misclassified as White on death certificates. Cancer information for AI/AN populations is known to be incomplete because the racial/ethnic status of many of these individuals is not correctly identified in medical and death records. 18 Although linkages between central cancer registries and Indian Health Service (IHS) records have improved incidence estimates for AI/AN populations, 17, 19 most estimates of cancer mortality currently available likely underestimate death rates in this population.
According to a study of data from the Alaska Tumor Registry, Alaska Native women have exhibited some of the highest IRs of cancer overall and different patterns of site-specific incidence compared with other US populations. 20 Reportedly, trends in cancer IRs among AI/AN people have been stable or decreasing, whereas cancer death rates have increased. 20 Although differences in overall cancer rates have been observed, 21 little is known about the rates of cancer of the uterine corpus and ovary in AI/AN populations. This article provides a detailed overview of the burden of cancer of the ovaries and uterine corpus among AI/AN populations. The main objective of this study was to improve our understanding of uterine and ovarian cancer incidence, stage at diagnosis, and mortality in AI/AN women relative to White women by minimizing the effect of racial misclassification in the cancer data. The secondary objective is to examine geographic differences and trends in incidence and mortality of ovarian and uterine cancer in AI/AN populations.
METHODS
Newly diagnosed cancers of the uterus and ovary from 1999 through 2009 were identified from the population-based central cancer registries participating in the Centers for Disease Control and Prevention's National Program of Cancer Registries and the National Cancer Institute's Surveillance, Epidemiology, and End Results program. For data to be included for a given year, registries had to meet data quality and completeness standards developed for US Cancer Statistics. 1 Participating behavior, and primary cancer site according to the 3rd edition of the International Classification of Diseases for Oncology (ICD-O-3). 22 We included only invasive cancers of the uterus (ICD-O-3 codes C540---C549 and C559), and ovaries (ICD-O-3 code C569) in our analysis.
More detailed description about data sources and methodology can be found elsewhere in this supplement. 13 To identify AI/AN cancer cases misclassified as other races, central cancer registries regularly link their cancer records with IHS patient registration files.
17 AI/AN individuals must provide proof of enrollment in a federally recognized tribe to receive health care from the IHS. The access to health care by IHS is greatest in Contract Health Service Delivery Area (CHSDA) counties, which, in general, contain, or are adjacent to, a federally recognized tribal reservation, tribal lands, or both.
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Standards for coding of stage of disease at diagnosis changed during the period of this study; therefore, we restricted the analysis of stage at diagnosis to incident cases diagnosed during the most recent years (2004---2009 23 
Mortality Data
We obtained mortality data from the Centers for Disease Control and Prevention's National Center for Health Statistics (NCHS). NCHS combined vital record death files obtained from each state to create the National Death Index and then linked it with the IHS patient registration database to determine vital status and cause of death of decedents who had received health care in IHS or tribal facilities.
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After this linkage, a flag indicating a positive link to IHS was added to the National Vital Statistics System's mortality file as an additional indicator of AI/AN ancestry. This death information is combined with corresponding annual bridged race intercensal population estimates to create an AI/AN---US Mortality Database within SEER*Stat version 8.0.4 (National Cancer Institute, Bethesda, MD). 25 This database combines race classification by NCHS on the basis of the death certificate and information derived from data linkages between the IHS patient registration database and the National Death Index. It includes every death for all races reported to NCHS from 1990 through 2009. 26 
Population Estimates
Bridged single-race population estimates developed by the US Census Bureau and NCHS and adjusted for population shifts resulting from Hurricanes Katrina and Rita in 2005 were included as denominators in the calculations of cancer incidence and death rates.
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Postcensal population denominators were racespecific, ethnicity-specific, and sex-specific county population estimates from the 2000 US Census, as modified by the Surveillance, Epidemiology, and End Results program and aggregated to the state and national levels. 17, 19 Bridged single-race data allowed for comparability between the pre-and post-2000 race/ ethnicity population estimates during this study period.
Geographic Coverage
To create most of the tabulations in this article, we restricted the analyses to IHS Contract Health Service Delivery Area or Tribal Service Delivery Area (abbreviated henceforth as "CHSDA" although TSDA are also implied) counties that, in general, contain federally recognized tribal or off-reservation trust land or are adjacent to tribal lands. 19 The IHS uses CHSDA residence to determine eligibility for services not directly available within the IHS. Linkage studies have indicated less misclassification of race for AI/AN population in these counties. 14, 19 The CHSDA counties also have 
Analysis
We analyzed incidence data from registries that met high quality criteria for publication in the annual US Cancer Statistics Web-based report. 1 The states that met quality criteria and were thus included in the analysis are listed in the footnotes of the tables. We excluded mortality data from Louisiana (1990), New Hampshire (1990 Hampshire ( ---1992 , and Oklahoma (1990---1996) because Hispanic origin was not collected on death certificates in those states for those years. We conducted all analyses using SEER*Stat version 8.0.4 (National Cancer Institute, Bethesda, MD). Age-adjusted death rates, IRs, standardized rate ratios (RRs), and 95% confidence intervals (CIs) were calculated for AI/AN women overall and by age group (< 50, 50---59, 60---69, ‡ 70 years) for all US counties and CHSDA counties and compared with those for White women. 33 During preliminary analyses, it was discovered that the updated bridged intercensal population estimates significantly overestimated AI/ANs of Hispanic origin. 34 Therefore, to avoid underestimating mortality and incidence in AI/ANs, we limited analyses to non-Hispanic AI/ANs. Non-Hispanic Whites were chosen as the most homogeneous referent group. For conciseness, the term "non-Hispanic" is omitted henceforth when discussing both groups. All rates are expressed per 100 000 and were age adjusted by the direct method to the 2000 US standard population (Census P25-1130). The 95% CIs were estimated using the Tiwari method. 35 We assessed temporal changes in annual age-adjusted incidence and death rates, including the annual percentage change (APC) for each interval, using Joinpoint regression techniques developed by the National Cancer Institute and available within the SEER*Stat software. 36 Statistical significance was set at a P level of less than .05.
RESULTS
Age-adjusted ovarian and uterine cancer death rates, RRs, and 95% CIs by IHS region for CHSDA counties and all US counties for AI/ AN women compared with White women are presented in Table 1 . There were 135 549 ovarian cancer deaths (death rate = 9.1) and 59 540 uterine cancer deaths (death rate = 3.9) among AI/AN and White women from 1999 through 2009. Of these, 705 ovarian and 314 uterine cancer deaths were among AI/AN women. In CHSDA counties, AI/AN women accounted 1.7% of ovarian and 1.8% of uterine cancer deaths. The death rate for ovarian cancer among AI/AN women residing in CHSDA counties was 9.0 per 100 000 women, whereas for uterine cancer it was 4.0. We observed that AI/AN and White women in CHSDA counties had similar death rates from ovarian cancer (9.0 vs 9.2) and uterine cancer 
Cancer Incidence Rates
Ovarian and uterine cancer case counts and age-adjusted IRs, RRs, and 95% CIs by IHS region, CHSDA county, and age group for AI/AN (Tables A and B , available as a supplement to the online version of this article at http://www.ajph.org). Conversely, the majority of uterine cancers were diagnosed at a localized stage, regardless of region (Tables C and D, available 
DISCUSSION
Our results demonstrated that, overall, ovarian and uterine cancer death rates in AI/AN women in CHSDA areas were similar to those in White women. We observed differences in IRs and death rates for ovarian and uterine cancer in AI/AN women by IHS region, with women in the Pacific Coast and Southern Plains having a higher ovarian cancer death rate and women in the Northern Plains having a higher uterine cancer death rate. Furthermore, comparing AI/AN women with White women, ovarian cancer death rates were higher in the Alaska, Southern Plains, and Southwest regions. Uterine cancer death rates, when comparing AI/AN women with White women, were higher in the Northern Plains, Southern Plains, Southwest, and Pacific Coast regions. Although overall uterine cancer IRs were marginally lower in AI/AN women in the Southern Plains, they were 35% higher than those of White women. Ovarian cancer IRs were also higher in AI/AN women than in White women in the Southern Plains. For AI/AN women aged 50 years or younger, uterine cancer IRs were higher than for White women. We observed, in comparison with White women, AI/AN women had a higher rate and proportion of ovarian cancer cases diagnosed at a distant stage and the majority of uterine cancers diagnosed at a localized stage.
To our knowledge, this study is the first focused on both ovarian and uterine cancers in AI/AN women using cancer incidence and mortality data that have been linked to improve race misclassification. Our ovarian cancer findings for all US counties were similar to a national study by Howe et al., 37 who also observed lower ovarian cancer death rates in American Indian women in comparison with White women, though this observation did not hold when looking only at CHSDA counties. As in our analysis, they also observed similar geographic variation in ovarian cancer rates, with AI/AN women in the Northeast region having the lowest rates. However, these data are from the 1990s, relied solely on vital statistics data, and did not consider Other studies describing ovarian and uterine cancer incidence and mortality have been limited to a particular geographic region or state. 6,38---41 In addition to potential misclassification of race, the incidence and mortality variations we observed among IHS regions may, in part, reflect geographic variations in environmental, social, and personal determinants of health. These geographic variations in IRs may highlight differences in the prevalence of risk factors such as obesity and physical activity known to be associated with both ovarian and uterine cancers. 42---44 According to Behavioral Risk Factor Surveillance System survey data, AI/AN women have a higher prevalence of obesity (35.4%) than White women (21.5) regardless of geographic region. 45 Also, AI/AN women are physically less active than White women (30.6% vs 22%), 45 and AI/AN women have a higher prevalence of cigarette smoking, especially in the Alaska, East, and Northern Plains regions. 45 In addition, hypertension and adult onset of diabetes mellitus are associated with increased risk of uterine cancer. 46, 47 AI/AN women have a higher prevalence of diabetes than White women (13.9% vs 6.9%), 45 and AI/AN women have been reported to have a higher rate of mortality as a result of diabetes than the general population. 48 Regional variations may also be caused by differences in other risk factors influencing ovarian and uterine cancer, such as pregnancy, long-term use of oral contraceptives, hormone replacement therapy, tubal ligation, or hysterectomy (with retention of the ovaries). 49 How many AI/AN women were exposed to postmenopausal hormone therapy is unknown. Observational epidemiologic evidence has strongly supported that tubal ligation and hysterectomy are associated with a decrease in the risk of ovarian cancer by approximately 26% to 30%. 50 AI/AN women had a higher prevalence of hysterectomy (23.1%) compared with White women (20.9%), and higher hysterectomy rates in AI/AN women decrease risk for uterine cancer. 51 In addition, trends in hysterectomy and oophorectomy may influence observed trends in ovarian and uterine cancer mortality. Tubal sterilization rates, which may influence rates of ovarian cancer, also vary by race. 52 To our knowledge, accurate counts of those who have intact ovaries and uteri are not available. Genetic variations may also partially explain observed geographic differences in IRs, though no large study has been done in AI/AN populations for genetic testing for familial cancers. Sporadic cases of breast and ovarian cancer suggestive of BRCA1/2 carriers as well as documentation of families diagnosed with Lynch syndrome have been found in Utah, Oklahoma, and Navajo Nation. 53 Observed variations in stage at diagnosis and death rates for ovarian and uterine cancer for AI/AN populations may be attributable to differences in diagnostic and treatment patterns. No screening tests are recommended for either ovarian or uterine cancer 54 ; however, differences in time of diagnosis may have resulted from differences in clinical presentation of both cancer types. Most uterine cancer presents with symptoms such as postmenopausal bleeding, and ovarian cancer presents with minimal or nonspecific symptoms such as bloating. 55 The lack of screening tests and the nonspecificity of symptoms result in later stage at diagnosis for both ovarian and uterine cancer. Public education and provider education may be important to affect stage at time of diagnosis, referral for appropriate and timely treatment, and ultimately survival. A molecular screening test, particularly for ovarian cancer, may change patterns of disease for a small segment of the population for whom genetic screening may be warranted. Prophylactic total hysterectomy has been shown to reduce risk of uterine and ovarian cancer in families with BRCA mutations or Lynch syndrome. 56 Finally, differences in mortality by geographic region may be reflective of geographic differences in the biological variation of the disease and access to state-of-the-art cancer care. The IHS has no gynecologic oncology surgeons, and therefore referral patterns may lead to delay in diagnosis and treatment that may affect death rates, but not IRs. 57 Although public service announcements such as the Centers for Disease Control and Prevention's Inside Knowledge campaign have been aimed at the general public, no concerted educational efforts have been made in AI/AN communities alerting women to the symptoms that require assessment by a clinician.
Limitations
Several limitations should be considered when interpreting results presented in this study. Even though the dataset used for this study was linked to the IHS patient registration dataset to improve misclassification of race for AI/AN cases, AI/AN persons who are not members of the federally recognized tribes, live in counties other than CHSDA counties, reside in urban areas, or are not eligible for IHS services are likely underrepresented. 17, 19 Of note is the last census showing that two thirds of AI/AN persons reside in urban areas and migrate back and forth to their tribal lands. AI/AN residents of urban areas differ from all AI/AN individuals in poverty level, health care access, and other factors that may influence incidence and mortality trends. 44, 58 Also, some eligible decedents may never have used IHS services and are therefore not included in the IHS database. Our findings suggest less variation for Whites than for AI/AN persons in regional analyses using data from CHSDA counties only. Perhaps an alternate aggregation of states or counties would reveal a different level of variation. Furthermore, bridged intercensal population estimates significantly overestimated AI/AN individuals of Hispanic origin, 34 limiting our ability to include all the AI/AN women in our analysis. 13, 19 Exclusion of Hispanic AI/AN individuals from the analysis reduced overall AI/AN deaths by less than 5% and may also have disproportionately excluded some tribal members residing in states along the US---Mexico border who have Hispanic surnames and may be coded as Hispanic at death.
Conclusions
This is the first comprehensive review of both incidence and mortality patterns for uterine and ovarian cancer in AI/AN women compared with White women in the same regions. Significant regional differences were found in these trends as for other cancers included in this supplement. More research is needed to identify and better understand the environmental, genetic, and clinical factors that may contribute to geographic differences in incidence and mortality among AI/AN populations. 
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